We investigate the role of ultrasound contrast agents for cardiovascular diagnostic imaging, and how these contrast agents can be used to treat problems like catheter-related thrombosis or vasospasm. 

We investigate the relationships between treatment modifiers, phenotypic factors and clinical outcomes in congenital heart disease.

We work on artificial intelligence algorithms for precision phenotyping and clinical trial design, and in the deployment and evaluation of those models in patient care settings. 

We study ways that new imaging technology can benefit patients with cardiovascular disease through precise assessment of myocardial function to provide accurate cardiac prognosis. 

We examine the processes involved in cardiovascular care, including provider practices, diagnostic tests and treatment options, all within the context of a healthcare system.

We explore methods to reveal the changes of right heart remodeling, discover imaging “biomarkers”, and to establish therapeutic targets for improving right heart function.